Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: results of a multicenter study after 12 months

Autor: Maria-Fernanda Guerra-Veloz, Juan-María Vázquez-Morón, María Belvis-Jiménez, Héctor Pallarés-Manrique, Teresa Valdés-Delgado, Luisa Castro-Laria, Belén Maldonado-Pérez, Antonio Benítez-Roldán, Raúl Perea-Amarillo, Vicente Merino, Ángel Caunedo-Álvarez, Ángel Vilches-Arenas, Federico Argüelles-Arias

Publikováno v: Revista Espanola de Enfermedades Digestivas, Vol 110, Iss 9, Pp 564-570 (2018)

ABSTRACT Background and aims: infliximab has changed the natural history of inflammatory bowel disease (IBD). The advent of biosimilar treatments such as CT-P13 will hopefully improve the availability of biological therapies. Data with regard to dru

Externí odkaz: https://doaj.org/article/0e6345d5ab5d4913be382ed841c819f6

Cut-off ranges of infliximab serum levels in Crohn�s disease in the clinical practice

Autor: María Fernanda Guerra Veloz, Vicente Merino Bohórquez, Antonia Sáez, Belén Maldonado Pérez, Raúl Perea Amarillo, Federico Argüelles Arias, Ángel Caunedo Álvarez, Luisa Castro Laria, Teresa Valdés Delgado

Publikováno v: Revista Española de Enfermedades Digestivas. 112

Introduction between 30 % and 40 % of patients treated with infliximab lose response during maintenance. Therapeutic drug monitoring could be used to optimize management in these situations. However, infliximab serum levels are not well defined. The

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5450f02a13b8192b02d86f101af1132c
https://doi.org/10.17235/reed.2020.6539/2019

Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data

Autor: Vicente Merino Bohórquez, Belén Maldonado Pérez, Teresa Valdés Delgado, Luisa Castro Laria, Ángel Vilches Arenas, Ángel Caunedo Álvarez, Federico Argüelles-Arias, Raúl Perea Amarillo, María Fernanda Guerra Veloz, María Belvis Jiménez

Publikováno v: idUS. Depósito de Investigación de la Universidad de Sevilla
instname
Therapeutic Advances in Gastroenterology
idUS: Depósito de Investigación de la Universidad de Sevilla
Universidad de Sevilla (US)
Therapeutic Advances in Gastroenterology, Vol 12 (2019)

Background: Several studies have reported positive efficacy outcomes for patients with inflammatory bowel disease treated with CT-P13, an infliximab biosimilar. Data from follow-up periods longer than 1 year are still scarce. Here, we assessed the lo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::acd351e4dd6f5c2f50271b105f91df80

Evolution of the incidence of inflammatory bowel disease in Southern Spain

Autor: Luisa Castro Laria, Ángel Caunedo Álvarez, Raúl Perea Amarillo, Eva Iglesias, Manuel Romero Gómez, Dina Chaaro Benallal, María Fernanda Guerra Veloz, Ángel Vilches, María Belén Maldonado Pérez, Valle Sánchez García, José Manuel Benítez, Federico Argüelles-Arias

Publikováno v: Revista Espanola de Enfermedades Digestivas, Vol 109, Iss 11, Pp 757-760
Revista Española de Enfermedades Digestivas v.109 n.11 2017
SciELO España. Revistas Científicas Españolas de Ciencias de la Salud
instname
Revista Española de Enfermedades Digestivas, Volume: 109, Issue: 11, Pages: 757-760, Published: NOV 2017

Background: The incidence of inflammatory bowel disease is increasing in Europe and in Spain. However, there is no recent data from Southern Spain. Objectives: To determine the evolution of the hospital incidence of inflammatory bowel disease in Sout

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d3d7d894e3789ad005e97ea02c8ec89
https://hdl.handle.net/10668/11474

Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data

Autor: María Fernanda Guerra Veloz, María Belvis Jiménez, Teresa Valdes Delgado, Luisa Castro Laria, Belén Maldonado Pérez, Raúl Perea Amarillo, Vicente Merino Bohórquez, Ángel Caunedo Álvarez, Ángel Vilches Arenas, Federico Argüelles-Arias

Publikováno v: Therapeutic Advances in Gastroenterology, Vol 12 (2019)

Background: Several studies have reported positive efficacy outcomes for patients with inflammatory bowel disease treated with CT-P13, an infliximab biosimilar. Data from follow-up periods longer than 1 year are still scarce. Here, we assessed the lo

Externí odkaz: https://doaj.org/article/712d953868004a109e0d565cd7a3e15a